Literature DB >> 3770373

A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease.

C Brignola, M Campieri, G Bazzocchi, P Farruggia, A Tragnone, G A Lanfranchi.   

Abstract

Currently there are no completely reliable methods for predicting an impending relapse in Crohn's disease. As approximately 50% of patients in remission [Crohn's disease activity index (CDAI) less than 150] show some laboratory abnormalities, we inquired whether these alterations might be of value for predicting relapse. We prospectively studied 41 patients with Crohn's disease who had been showing CDAI less than 150 for at least 6 mo before entering the study and who were not receiving any long-term treatment. The 41 patients were studied at the ninth and at the 18th month after inclusion in the study. Disease activity was monitored by CDAI calculation and by measurement of erythrocyte sedimentation rate, white blood cell count, hemoglobin, albumin, alpha 2-globulin, serum iron, C-reactive protein, alpha 1-glycoprotein, and alpha 2-antitrypsin. Seventeen of the 41 patients had a clinical relapse during follow-up. At the beginning of the study the patients who later relapsed showed a remarkable alteration of acid alpha 1-glycoprotein (p less than 0.0001), alpha 2-globulin (p less than 0.0003), and erythrocyte sedimentation rate (p less than 0.0006), in comparison with the patients who remained in remission. by discriminant analysis a prognostic index with these laboratory investigations provided a high percentage (88%) of accuracy according to the outcome at the 18th month.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770373     DOI: 10.1016/0016-5085(86)90206-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

Review 1.  Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?

Authors:  D S Pardi; W J Sandborn
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 2.  Recurrence rates in Crohn's disease: predicting the future and predicting the past.

Authors:  D B Sachar
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

3.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

4.  European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 5.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

6.  Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse.

Authors:  E Louis; J Belaiche; C Van Kemseke; N Schaaf; P Mahieu; J Y Mary
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

7.  CT enterography as a powerful tool for the evaluation of inflammatory activity in Crohn's disease: relationship of CT findings with CDAI and acute-phase reactants.

Authors:  Giuseppe Lo Re; Maria Cappello; Chiara Tudisca; Massimo Galia; Claudia Randazzo; Antonio Craxì; Calogero Cammà; Andrea Giovagnoni; Massimo Midiri
Journal:  Radiol Med       Date:  2014-01-10       Impact factor: 3.469

8.  Analysis of biological variables in Crohn's disease.

Authors:  C Brignola; C Belloli; G De Simone; M Campieri; P Gionchetti; A Belluzzi
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

9.  Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution?

Authors:  T Sahmoud; J Y Mary; T Sahmoud
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

Review 10.  Proteomics in Inflammatory Bowel Disease: Approach Using Animal Models.

Authors:  Fadi H Mourad; Yunki Yau; Valerie C Wasinger; Rupert W Leong
Journal:  Dig Dis Sci       Date:  2017-07-17       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.